Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Malignant hyperthermia: considerations for the general surgeon Heggie JECan J Surg 2002[Oct]; 45 (5): 369-72Malignant hyperthermia is a potentially fatal genetic myopathy that presents when the patient is under anesthesia. It manifests as a hypermetabolic state involving tachycardia, hypercarbia, base deficit, rigidity and fever. Many of the hallmark traits of an acute malignant hyperthermic crisis overlap with signs and symptoms of an emergent abdominal condition. Historically, there has been a reluctance in local community hospitals to manage patients known to be susceptible to malignant hyperthemia, and this is a source of frustration for many families in which there is a history of this condition. This article outlines the diagnosis and management of an acute malignant hyperthermic crisis from the viewpoint of a community general surgeon and provides a review of the management of patients known to be susceptible to this condition in the surgeon's elective and emergent practice.|Anesthetics, Inhalation/adverse effects[MESH]|Biopsy[MESH]|Dantrolene/therapeutic use[MESH]|General Surgery[MESH]|Genetic Predisposition to Disease[MESH]|Humans[MESH]|Malignant Hyperthermia/*diagnosis/etiology/*therapy[MESH]|Monitoring, Physiologic/methods[MESH]|Muscle Relaxants, Central/therapeutic use[MESH]|Muscle, Skeletal/pathology[MESH]|Neuromuscular Nondepolarizing Agents/adverse effects[MESH] |
